Avaliação do complexo metálico ternário de cobre associado a 2-(4-fluorofenoxi), aceto-hidrazida, perclorato e 1,10 fenantrolina (DRI-12) em células somáticas de Drosophila melanogaster

• Ano de defesa: 2020
• Autor(a) principal: Bontempo, Nayara Junia de Souza
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Uberlândia; Brasil; Programa de Pós-graduação em Biotecnologia
• Palavras-chave em Português: Câncer; Cobre; DRI-12; Drosophila melanogaster; CNPQ::CIENCIAS AGRARIAS
• Link de acesso: https://repositorio.ufu.br/handle/123456789/28892; http://doi.org/10.14393/ufu.di.2020.269

Cancer is the second leading cause of death in the world, and about 18 million people are diagnosed with some type of this disease. Targeted treatments and new drugs increase patient’s survival. However, resistance and comorbidities are still frequent, highlighting the need for more selective compounds, less toxic and capable of combating the resistance of tumor cells. In this sense, this study aimed to evaluate the mutagenic, recombinogenic, carcinogenic and/or anticarcinogenic potential of a copper compound associated with 2- (4-fluorophenoxy), acetohydrazide, perchlorate and 1.10 phenanthroline (DRI-12). In vivo experiments were carried out on Drosophila melanogaster, which are: the test for detection of epithelial tumor clones (ETT), to assess the anticarcinogenic potential, and the somatic mutation and recombination test (SMART), to verify the mutagenicity/recombinogenicity of the metal complex. The samples, alone and in association with Doxorubicin (DXR), were used at 0.015; 0.031; 0.062; 0.125 and 0.250mM, based on the toxicity test (TX). Regarding the SMART test, DRI-12 did not show mutagenic/recombinogenic potential. In the treatment associated with DXR, there was a reduction in the frequency of spots in all concentrarions tested, when compared to the positive control (DXR at 0.4mM). For ETT test (co and post-treatment) there was no carcinogenic effect and the modulating activity of the compound DRI-12 on the action of DXR was evident, since the tumors significantly reduced (p<0.05) when compared to positive control. Our results suggest a new promising metallic compound in the treatment of cancer, being necessary to validate for different tumor types.